Katherine E. Lewis

Katherine E. Lewis

Auto-generated profile, based on publicly available information

Katherine E. Lewis

Menzies Institute for Medical Research University of Tasmania Hobart Tasmania 7000 Australia

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2017 in Nature Neuroscience
Verified
Journal Article
Open access
PDF file
CWCallum Walker
Callum Walker
SHSaul Herranz-Martin
Saul Herranz-Martin
EKEvangelia Karyka
Evangelia Karyka
CLChunyan Liao
Chunyan Liao
KLKatherine Lewis
Katherine Lewis
SESherif El-Khamisy
Sherif El-Khamisy
An expanded repetition of a DNA sequence within the C9orf72 gene is the most common genetic cause for motor neuron disease and frontotemporal dementia. In this study, the authors show that this expansion causes increased genomic breaks and reduces the cell's ability to repair the breaks, ultimately leading to neuronal cell death. Hexanucleotide repeat expansions represent the most common genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia, though the mechanisms by which such expansions cause neurodegeneration are poorly understood. We report elevated levels of DNA–RNA hybrids (R-loops) and double strand breaks in rat neurons, human cells and C9orf72 ALS patient spinal cord tissues. Accumulation of endogenous DNA damage is concomitant with defective ATM-mediated DNA repair signaling and accumulation of protein-linked DNA breaks. We reveal that defective ATM-mediated DNA repair is a consequence of P62 accumulation, which impairs H2A ubiquitylation and perturbs ATM signaling. Virus-mediated expression of C9orf72-related RNA and dipeptide repeats in the mouse central nervous system increases double strand breaks and ATM defects and triggers neurodegeneration. These findings identify R-loops, double strand breaks and defective ATM-mediated repair as pathological consequences of C9orf72 expansions and suggest that C9orf72-linked neurodegeneration is driven at least partly by genomic instability.

23 March 2014 in Journal of Neuroinflammation
Verified
Journal Article
Open access
PDF file
KLKatherine E Lewis
Katherine E Lewis
ARAnna L Rasmussen
Anna L Rasmussen
WBWilliam Bennett
William Bennett
AKAnna King
Anna King
AWAdrian K West
Adrian K West
MCMeng Inn Chuah
Meng Inn Chuah
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease affecting the motor system. Although the etiology of the disease is not fully understood, microglial activation and neuroinflammation are thought to play a role in disease progression.

1 January 2016 in Molecular Therapy - Methods & Clinical Development
Verified
Journal Article
Open access
VLVera Lukashchuk
Vera Lukashchuk
KLKatherine E Lewis
Katherine E Lewis
ICIan Coldicott
Ian Coldicott
AGAndrew J Grierson
Andrew J Grierson
MAMimoun Azzouz
Mimoun Azzouz
An international, open-access journal publishing top-quality, novel methods and technology development, as well as significant improvements to established techniques in basic, translational, and clinical cell and gene therapy.

1 September 2018 in Molecular Therapy Nucleic Acids
Verified
Journal Article
Open access
TITommaso Iannitti
Tommaso Iannitti
JSJoseph M. Scarrott
Joseph M. Scarrott
SLShibi Likhite
Shibi Likhite
ICIan R.P. Coldicott
Ian R.P. Coldicott
KLKatherine E. Lewis
Katherine E. Lewis
MAMimoun Azzouz
Mimoun Azzouz
Of familial amyotrophic lateral sclerosis (fALS) cases, 20% are caused by mutations in the gene encoding human cytosolic Cu/Zn superoxide dismutase (hSOD1). Efficient translation of the therapeutic potential of RNAi for the treatment of SOD1-ALS patients requires the development of vectors that are free of significant off-target effects and with reliable biomarkers to discern sufficient target engagement and correct dosing. Using adeno-associated virus serotype 9 to deliver RNAi against hSOD1 in the SOD1G93A mouse model, we found that intrathecal injection of the therapeutic vector via the cisterna magna delayed onset of disease, decreased motor neuron death at end stage by up to 88%, and prolonged the median survival of SOD1G93A mice by up to 42%. To our knowledge, this is the first report to demonstrate no significant off-target effects linked to hSOD1 silencing, providing further confidence in the specificity of this approach. We also report the measurement of cerebrospinal fluid (CSF) hSOD1 protein levels as a biomarker of effective dosing and efficacy of hSOD1 knockdown. Together, these data provide further confidence in the safety of the clinical therapeutic vector. The CSF biomarker will be a useful measure of biological activity for translation into human clinical trials.

1 March 2015 in Disease Models & Mechanisms
Verified
Journal Article
Open access
PDF file
CBCatherine Blizzard
Catherine Blizzard
KSKatherine A. Southam
Katherine A. Southam
EDEdgar Dawkins
Edgar Dawkins
KLKatherine E. Lewis
Katherine E. Lewis
AKAnna E. King
Anna E. King
TDTracey Dickson
Tracey Dickson
There is a desperate need for targeted therapeutic interventions that slow the progression of amyotrophic lateral sclerosis (ALS). ALS is a disorder with heterogeneous onset, which then leads to common final pathways involving multiple neuronal compartments that span both the central and peripheral nervous system. It is believed that excitotoxic mechanisms might play an important role in motor neuron death in ALS. However, little is known about the mechanisms by which excitotoxicity might lead to the neuromuscular junction degeneration that characterizes ALS, or about the site at which this excitotoxic cascade is initiated. Using a novel compartmentalised model of site-specific excitotoxin exposure in lower motor neurons in vitro, we found that spinal motor neurons are vulnerable to somatodendritic, but not axonal, excitotoxin exposure. Thus, we developed a model of somatodendritic excitotoxicity in vivo using osmotic mini pumps in Thy-1-YFP mice. We demonstrated that in vivo cell body excitotoxin exposure leads to significant motor neuron death and neuromuscular junction (NMJ) retraction. Using confocal real-time live imaging of the gastrocnemius muscle, we found that NMJ remodelling preceded excitotoxin-induced NMJ degeneration. These findings suggest that excitotoxicity in the spinal cord of individuals with ALS might result in a die-forward mechanism of motor neuron death from the cell body outward, leading to initial distal plasticity, followed by subsequent pathology and degeneration.

1 May 2019 in Disease Models & Mechanisms
Verified
Journal Article
Open access
PDF file
TJTongcui Jiang
Tongcui Jiang
EHEmily Handley
Emily Handley
MBMariana Brizuela
Mariana Brizuela
EDEdgar Dawkins
Edgar Dawkins
KLKatherine E. A. Lewis
Katherine E. A. Lewis
CBCatherine Blizzard
Catherine Blizzard
Altered cortical excitability and synapse dysfunction are early pathogenic events in amyotrophic lateral sclerosis (ALS) patients and animal models. Recent studies propose an important role for TAR DNA-binding protein 43 (TDP-43), the mislocalization and aggregation of which are key pathological features of ALS. However, the relationship between ALS-linked TDP-43 mutations, excitability and synaptic function is not fully understood. Here, we investigate the role of ALS-linked mutant TDP-43 in synapse formation by examining the morphological, immunocytochemical and excitability profile of transgenic mouse primary cortical pyramidal neurons that over-express human TDP-43A315T. In TDP-43A315T cortical neurons, dendritic spine density was significantly reduced compared to wild-type controls. TDP-43A315T over-expression increased the total levels of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropinionic acid (AMPA) glutamate receptor subunit GluR1, yet the localization of GluR1 to the dendritic spine was reduced. These postsynaptic changes were coupled with a decrease in the amount of the presynaptic marker synaptophysin that colocalized with dendritic spines. Interestingly, action potential generation was reduced in TDP-43A315T pyramidal neurons. This work reveals a crucial effect of the over-expression mutation TDP-43A315T on the formation of synaptic structures and the recruitment of GluR1 to the synaptic membrane. This pathogenic effect may be mediated by cytoplasmic mislocalization of TDP-43A315T. Loss of synaptic GluR1, and reduced excitability within pyramidal neurons, implicates hypoexcitability and attenuated synaptic function in the pathogenic decline of neuronal function in TDP-43-associated ALS. Further studies into the mechanisms underlying AMPA receptor-mediated excitability changes within the ALS cortical circuitry may yield novel therapeutic targets for treatment of this devastating disease.